Oral versus topical ibuprofen for chronic knee pain: A prospective randomized pilot study

Pain Physician

Volumn 13, Issue 5, 2010, Pages 457-467

  Tiso, Robert L ^a   Tong Ngork, Sarani ^b   Fredlund, Katherine L ^b  

^a New York Spine and Wellness Center   (United States)

^b NONE

Author keywords

Chronic pain; Knee osteoarthritis; Topical ibuprofen

Indexed keywords

IBUPROFEN;

ACUTE DISEASE; ADULT; ANALGESIA; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; FEMALE; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; INTERMETHOD COMPARISON; KNEE PAIN; MALE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT SATISFACTION; PILOT STUDY; PRIVATE PRACTICE; RANDOMIZED CONTROLLED TRIAL; RASH; SHORT FORM 12; STOMACH PAIN;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; FEMALE; HUMANS; IBUPROFEN; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN; PILOT PROJECTS;

EID: 77957985395     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41:778-799.
2. Felson DT, Naimark A, Anderson J, Kazis L, Castelli W, Meenan RF. The prevalence of knee osteoarthritis in the elderly: the Framingham Osteoarthritis Study. Arthritis Rheum 1987; 30:914-918.
3. Dawson J, Linsell L, Zondervan K, Rose P, Randall T, Carr A, Fitzpatrick R. Epidemiology of hip and knee pain and its impact on overall health status in older adults. Rheumatology 2004; 43:497-504.
4. Quintana JM, Escobar A, Arostegui I, Bilbao A, Armendariz P, Lafuente I, Agirre U. Prevalence of symptoms of knee or hip joints in older adults from the general population. Aging Clin Exp Res 2008; 20:329-336.
5. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991; 325:87-91.
6. Boureau F, Schneid H, Zeghari N, Wall R, Bourgeois P. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip. Ann Rheum Dis 2004; 63:1028-1034.
7. Schiff M, Minic M. Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and Ibuprofen in the treatment of osteoarthritis of the knee. J Rheumatol 2004; 31:1373-1383.
8. Puopolo A, Boice JA, Fidelholtz JL, Littlejohn TW, Miranda P, Berrocal A, Ko A, Cichanowitz N, Reicin AS. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage 2007; 15:1348-1356.
9. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A metaanalysis. Ann Intern Med 1991; 115:787-796.
10. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340:1888-1899.
11. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial. Lancet 2004; 364:665-674.
12. Schaffer D, Florin T, Eagle C, Marschner I, Singh G, Grobler M, Fenn C, Schou M, Curnow KM. Risk of serious NSAIDrelated gastrointestinal events during long-term exposure: A systematic review. Med J Aust 2006; 185:501-506.
13. Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs: An instrumental variable analysis. Arthritis Rheum 2006; 54:3390-3398.
14. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: An underrecognized public health problem. Arch Intern Med 2000; 160:777-784.
15. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332:1302-1308.
16. Morrison A, Ramey DR, van Adelsberg J, Watson DJ. Systematic review of trials of the effect of continued use of oral nonselective NSAIDs on blood pressure and hypertension. Curr Med Res Opin 2007; 23:2395-2404.
17. Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991; 115:165-172.
18. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000; 151:488-496.
19. Campbell J, Dunn T. Evaluation of topical ibuprofen cream in the treatment of acute ankle sprains. J Accid Emerg Med 1994; 11:178-182.
20. Moore RA, Tramèr MR, Carroll D, Wiffen PJ, McQuay HJ. Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ 1998; 316:333-338.
21. Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs 2000; 60:555-574.
22. Rovensky J, Miceková D, Gubzová Z, Fimmers R, Lenhard G, Vögtle-Junkert U, Schreyger F. Treatment of knee osteoarthritis with a topical non-steroidal antiinflammatory drug. Results of a randomized, double-blind, placebocontrolled study on the efficacy and safety of a 5% ibuprofen cream. Drugs Exp Clin Res 2001; 27:209-221.
23. Mason L, Moore RA, Edwards JE, Derry S, McQuay HJ. Topical NSAIDs for acute pain: a meta-analysis. BMC Fam Pract 2004; 5:10.
24. Rovensky J, Svík K, Istok R, Stancíková M. Quantitative assessment of markers of inflammation, arthritis and pain in rats with adjuvant arthritis following the treatment with ibuprofen cream and placebo. Drugs Exp Clin Res 2003; 29:85-90.
25. Trnavsky K, Fischer M, Vögtle-Junkert U, Schreyger F. Efficacy and safety of 5% ibuprofen cream treatment in knee osteoarthritis. Results of a randomized, double-blind, placebo-controlled study. J Rheumatol 2004; 31:565-572.
26. Mason L, Moore RA, Edwards JE, Derry S, McQuay HJ. Topical NSAIDs for chronic musculoskeletal pain: Systematic review and meta-analysis. BMC Musculoskelet Disord 2004; 5:28.
27. Cross PL, Ashby D, Harding G, Hennessy EM, Letley L, Parsons S, Spencer AE, Underwood M; TOIB Study Team. TOIB Study. Are topical or oral ibuprofen equally effective for the treatment of chronic knee pain presenting in primary care: A randomised controlled trial with patient preference study. BMC Musculoskelet Disord 2005; 6:55.
28. Underwood M, Ashby D, Cross P, Hennessy E, Letley L, Martin J, Mt-Isa S, Parsons S, Vickers M, Whyte K; TOIB study team. Advice to use topical or oral ibuprofen for chronic knee pain in older people: Randomised controlled trial and patient preference study. BMJ 2008; 336:138-142.
29. Whitefield M, O'Kane CJ, Anderson S. Comparative efficacy of a proprietary topical ibuprofen gel and oral ibuprofen in acute soft tissue injuries: a randomized, double-blind study. J Clin Pharm Ther 2002; 27:409-417.
30. Elliott AM, Smith BH, Smith WC, Chambers WA. Changes in chronic pain severity over time: the Chronic Pain Grade as a valid measure. Pain 2000; 88:303-308.
31. Dixon D, Pollard B, Johnston M. What does the chronic pain grade questionnaire measure? Pain 2007; 130:249-253.
32. Bellamy, Nicholas. WOMAC Osteoarthritis Index User Guide VIII 2007.
33. ® Health Survey. Lincoln, RI: QualityMetric Incorporated, 2008.
34. Machen J, Whitefield M. Efficacy of a proprietary ibuprofen gel in soft tissue injuries: a randomised, double-blind, placebo-controlled study. Int J Clin Pract 2002; 56:102-106.
35. Davies GM, Watson DJ, Bellamy N. Comparison of the responsiveness and relative effect size of the western Ontario and McMaster Universities Osteoarthritis Index and the short-form Medical Outcomes Study Survey in a randomized, clinical trial of osteoarthritis patients. Arthritis Care Res 1999; 12:172-179.
36. Dominkus M, Nicolakis M, Kotz R, Wilkinson FE, Kaiser RR, Chlud K. Comparison of tissue and plasma levels of ibuprofen after oral and topical administration. Arzneimittelforschung 1996; 46:1138-1143.
37. Tegeder I, Muth-Selbach U, Lötsch J, Rüsing G, Oelkers R, Brune K, Meller S, Kelm GR, Sörgel F, Geisslinger G. Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration. Clin Pharmacol Ther 1999; 65:357-368.
38. Kleinbloesem CH, Ouwerkerk M, Spitznagel W, Wilkinson FE, Kaiser RR. Pharmacokinetics and bioavailability of percutaneous ibuprofen. Arzneimittelforschung 1995; 45:1117-1121.
39. Steen AE, Reeh PW, Geisslinger G, Steen KH. Plasma levels after peroral and topical ibuprofen and effects upon low pH-induced cutaneous and muscle pain. Eur J Pain 2000; 4:195-209.
40. Cross PL. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361:1560-1561; author reply 1561.
41. Curtis JP, Krumholz HM. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361:1560; author reply 1561.
42. Etminan M, Samii A. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361:1558-1159; author reply 1559.
43. Jerie P. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361:1559; author reply 1559.
44. Smout J, Cleanthis M, Stansby G. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361:1559-1560; author reply 1561.
45. Weiss HJ. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361:1560; author reply 1561.
46. Cheema AA. Should people on aspirin avoid Ibuprofen? A review of the literature. Cardiol Rev 2004; 12:174-176.
47. Cryer B, Berlin RG, Cooper SA, Hsu C, Wason S. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. Clin Ther 2005; 27:185-191.
48. MacDonald TM, Wei L. Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen? Basic Clin Pharmacol Toxicol 2006; 98:275-280.
49. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361:573-574.
50. Sopena F, Lanas A. How to advise aspirin use in patients who need NSAIDs. Curr Pharm Des 2007; 13:2248-2260.
51. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007; 370:2138-2151.